Literature DB >> 30359772

Imbalance of the two main circulating dendritic cell subsets in patients with myasthenia gravis.

Pei Chen1, Yingkai Li1, Hao Huang2, Yan Li3, Xin Huang1, Zhenguang Chen4, Xiaoxi Liu1, Li Qiu1, Changyi Ou1, Zhidong Huang1, Zhongqiang Lin1, Hao Ran5, Weibin Liu6.   

Abstract

Although it is well documented that circulating dendritic cells (DCs) have specialized features during many kinds of physiological and pathological conditions, there are few reports about the features of DCs in the peripheral blood of myasthenia gravis (MG) patients. We investigated the quantitative and component features of DCs and their implications in MG. Peripheral blood samples from different kinds of MG patients were collected and their clinical characteristics were recorded. Using flow cytometry, we distinguished circulating DC subsets [plasmacytoid DCs (pDCs) and myeloid DCs (mDCs)] and enumerated their densities in peripheral blood. Absolute numbers of circulating pDCs were significantly decreased in naïve MG patients compared with healthy controls, resulting in a markedly lower ratio of the pDC to mDC percentage in total circulating DCs (pDCs/mDCs), suggesting an imbalance in the proportions of the two main circulating DC subsets. The clinical status of MG patients was improved after drug treatment, together with increased pDCs/mDCs. In a longitudinal follow-up, we observed that circulating mDCs were significantly reduced after 1 month of therapy with a corticosteroid and immunosuppressant, resulting in recovery of pDCs/mDCs. Although the exact meaning of the proportion change in circulating DC subsets is unknown, pDCs/mDCs might reflect the balance between the autoimmune response and immune tolerance of a patient. Moreover, changes in pDCs/mDCs during treatment might be a promising marker to predict the efficacy of a specific drug used for MG patients.
Copyright © 2018. Published by Elsevier Inc.

Entities:  

Keywords:  Corticosteroid; Immunosuppressant; Myasthenia gravis; Myeloid dendritic cells; Plasmacytoid dendritic cells; pDCs/mDCs

Mesh:

Substances:

Year:  2018        PMID: 30359772     DOI: 10.1016/j.clim.2018.10.012

Source DB:  PubMed          Journal:  Clin Immunol        ISSN: 1521-6616            Impact factor:   3.969


  1 in total

1.  DCAF12 and HSPA1A May Serve as Potential Diagnostic Biomarkers for Myasthenia Gravis.

Authors:  Weidong Nong; Fang Huang; Fengping Mao; Dayuan Lao; Zhuowei Gong; Wen Huang
Journal:  Biomed Res Int       Date:  2022-05-24       Impact factor: 3.246

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.